STOCK TITAN

VBI Vaccines Inc. - $VBIV STOCK NEWS

Welcome to our dedicated page for VBI Vaccines news (Ticker: $VBIV), a resource for investors and traders seeking the latest updates and insights on VBI Vaccines stock.

VBI Vaccines Inc. (NASDAQ: VBIV) is a leading biopharmaceutical company focused on developing next-generation vaccines to meet unmet needs in infectious diseases and immuno-oncology. Headquartered in Cambridge, MA, with research facilities in Ottawa, Canada, VBI is at the forefront of vaccine innovation with two primary platforms.

The first platform, Enveloped Virus-Like Particle (eVLP), enables the design of vaccines that closely mimic the target virus, enhancing their effectiveness. The company's lead eVLP asset is a prophylactic cytomegalovirus (CMV) vaccine, currently advancing with GMP manufacturing for formal preclinical and Phase I trials.

The second platform is a thermostable technology allowing vaccines and biologics to withstand fluctuating temperatures during storage and transport. VBI has completed proof-of-concept thermostability studies on several vaccine and biologic targets, highlighting this platform's potential to improve global vaccine distribution.

VBI's commercial product, Sci-B-Vac, is a hepatitis B (HBV) vaccine approved for adults, children, and newborns. The company's innovations are designed to address significant gaps in the vaccine market, particularly in underserved areas.

Recent achievements include the initiation of GMP manufacturing for its CMV vaccine candidate and successful proof-of-concept studies for its thermostable technology. VBI continues to be a pivotal player in the biopharmaceutical field, dedicated to advancing public health through cutting-edge vaccine solutions.

Rhea-AI Summary

VBI Vaccines shared interim data from the Phase 2b study of its cancer vaccine VBI-1901 in recurrent glioblastoma (rGBM) patients. Results showed a 67% tumor reduction in one patient, with a 43% disease control rate in the treatment group versus 0% in the control group. The FDA has granted Fast Track and Orphan Drug Designations to VBI-1901. Additional data will be available in Q4 2024. The study aims to enroll 60 patients by year-end.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.81%
Tags
-
Rhea-AI Summary

VBI Vaccines announced that new interim tumor response data from its ongoing Phase 2b study of VBI-1901, a cancer vaccine candidate for recurrent glioblastoma (GBM), will be presented at the 2024 ASCO Annual Meeting. The data include updates on patients from the initial evaluation and new patients randomized into the study. The study involves 60 patients, randomized into two arms: VBI-1901 combined with GM-CSF, and standard-of-care treatment. Key endpoints are safety, overall survival, tumor response rate, progression-free survival, immunologic responses, corticosteroid use reduction, and quality of life changes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.54%
Tags
-
Rhea-AI Summary

VBI Vaccines (NASDAQ: VBIV) reported substantial growth in its first quarter 2024 financial results. Global net revenue for PreHevbrio, their Hepatitis B vaccine, surged 105% year-over-year to $1.0 million. VBI-1901, their cancer vaccine, showed encouraging early data in glioblastoma patients, with more results expected later in 2024. The company expanded its strategic partnership with the Canadian Government to develop its MLE technology, backed by CAD$28 million in funding. Financial highlights include a decrease in cost of revenues to $2.7 million and a reduction in R&D expenses to $2.6 million. Despite net losses, the company reduced its operating cash outflow by 46% year-over-year. SG&A expenses dropped 42% due to organizational changes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.52%
Tags
Rhea-AI Summary
VBI Vaccines Inc. (VBIV) reports a 234% increase in global net revenue for PreHevbrio® (Hepatitis B Vaccine [Recombinant]) from 2022 to 2023. Preliminary 2024 U.S. sales show significant growth, with 65% of 2023 volume sold in Q1 2024. Positive early data from Phase 2b study of VBI-1901 in recurrent glioblastoma. The company focuses on financial stability, debt reduction, and operational efficiency to drive sustainable growth and value for stakeholders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.9%
Tags
-
Rhea-AI Summary
VBI Vaccines Inc. (VBIV) closes a registered direct offering, raising approximately $2 million. The offering included 2,272,728 common shares and warrants at $0.88 per share. The net proceeds will be used for working capital and general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.33%
Tags
-
Rhea-AI Summary
VBI Vaccines Inc. (VBIV) announces a registered direct offering of 2,272,728 common shares at $0.88 per share and unregistered warrants to purchase up to 2,272,728 common shares with an exercise price of $0.76 per share.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-28.34%
Tags
Rhea-AI Summary
VBI Vaccines Inc. presents promising early tumor response data from Phase 2b study of VBI-1901 in recurrent glioblastoma at World Vaccine Congress 2024
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.14%
Tags
-
Rhea-AI Summary
VBI Vaccines expands collaboration with the Canadian government to accelerate development of its novel MLE technology platform. The partnership will direct CAD$28 million towards VBI's proprietary technology platforms, including the MLE platform, showing promising preclinical results and potential for streamlined manufacturing timelines.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.9%
Tags
partnership
-
Rhea-AI Summary
VBI Vaccines Inc. (VBIV) announced agreements with Brii Biosciences for up to $33 million in consideration, involving the acquisition of intellectual property, manufacturing capabilities, and exclusive licensing for immunotherapeutic candidates. The deal aims to reduce VBI's debt and enhance financial stability.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.12%
Tags
none
Rhea-AI Summary
Brii Biosciences Limited acquires all intellectual properties related to BRII-179, eliminates future milestone and royalty payments to VBI, and secures rights to VBI-1901 APAC, expanding global commercial supplies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.12%
Tags

FAQ

What does VBI Vaccines Inc. focus on?

VBI Vaccines Inc. focuses on developing next-generation vaccines to address unmet needs in infectious diseases and immuno-oncology.

Where is VBI Vaccines Inc. headquartered?

VBI Vaccines Inc. is headquartered in Cambridge, MA, with research facilities in Ottawa, Canada.

What is the eVLP platform?

The eVLP platform allows for the design of enveloped virus-like particle vaccines that closely mimic the target virus, enhancing their effectiveness.

What is VBI's lead eVLP asset?

VBI's lead eVLP asset is a prophylactic cytomegalovirus (CMV) vaccine currently advancing with GMP manufacturing for preclinical and Phase I trials.

What is the thermostable technology platform?

The thermostable technology platform enables the development of vaccines and biologics that can withstand fluctuating temperatures during storage and transport.

What is Sci-B-Vac?

Sci-B-Vac is a hepatitis B (HBV) vaccine developed by VBI Vaccines Inc. for adults, children, and newborns.

What are the recent achievements of VBI Vaccines Inc.?

Recent achievements include the initiation of GMP manufacturing for its CMV vaccine candidate and successful proof-of-concept studies for its thermostable technology.

What markets does VBI aim to serve?

VBI aims to serve large underserved markets, addressing significant gaps in the vaccine market, particularly in infectious diseases and immuno-oncology.

How does VBI's thermostable technology benefit global vaccine distribution?

VBI's thermostable technology benefits global vaccine distribution by enabling vaccines to withstand fluctuating temperatures during storage and transport, improving their accessibility in diverse regions.

What stage is VBI's CMV vaccine candidate currently in?

VBI's CMV vaccine candidate is currently in the GMP manufacturing stage, advancing towards formal preclinical and Phase I trials.

VBI Vaccines Inc.

Nasdaq:VBIV

VBIV Rankings

VBIV Stock Data

17.15M
26.73M
6.77%
13.03%
1.05%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States of America
CAMBRIDGE